title: Anidulafungin Vicuron.
abstract: Anidulafungin, a 1,3-beta-glucan synthesis inhibitor and the pentyloxyterphenyl side chain derivative of echinocandin B, is being developed by Vicuron Pharmaceuticals Inc, under license from Eli Lilly & Co, for the potential treatment of fungal infection.
authors.affiliation: Servicio de Microbiologica Clinica, Hospital Universitario de Valme, Seville, Spain. estrella.martin.sspa@juntadeandalucia.es
authors.forename: Estrella
authors.initials: E
authors.lastname: Martin-Mazuelos
mesh_terms: D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D054714:Echinocandins; D006801:Humans; D010456:Peptides, Cyclic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D015507:Drugs, Investigational; D054714:Echinocandins; D010456:Peptides, Cyclic; D000077612:Anidulafungin